Neuroendocrine carcinoma of uterine cervix findings shown by MRI for staging and survival analysis – Japan multicenter study

Objectives: To investigate neuroendocrine carcinoma (NEC) of the uterine cervix cases for MRI features and staging, as well as pathological correlations and survival. Results: FIGO was I in 42, II in 14, III in 1, and IV in 5 patients. T2-weighted MRI showed homogeneous slightly high signal intensity and obvious restricted diffusion (ADC map, low intensity; DWI, high intensity) throughout the tumor in most cases, and mild enhancement in two-thirds. In 50 patients who underwent a radical hysterectomy and lymphadenectomy without neoadjuvant chemotherapy (NAC), intrapelvic T staging by MRI overall accuracy was 88.0% with reference to pathology staging, while patient-based sensitivity, specificity, and accuracy for metastatic pelvic lymph node detection was 38.5%, 100%, and 83.3%, respectively. During a mean follow-up period of 45.6 months (range 4.3–151.0 months), 28 patients (45.2%) experienced recurrence and 24 (38.7%) died. Three-year progression-free and overall survival rates for FIGO I, II, III, and IV were 64.3% and 80.9%, 50% and 64.3%, 0% and 0%, and 0% and 0%, respectively. Materials and Methods: Sixty-two patients with histologically surgery-proven uterine cervical NEC were enrolled. Twelve received NAC. Clinical data, pathological findings, and pretreatment pelvic MRI findings were retrospectively reviewed. Thirty-two tumors were pure NEC and 30 mixed with other histotypes. The NECs were small cell type (41), large cell type (18), or a mixture of both (3). Conclusions: Homogeneous lesion texture with obvious restricted diffusion throughout the tumor are features suggestive of cervical NEC. Our findings show that MRI is reliable for T staging of cervical NEC.

[1]  S. Faria,et al.  Staging MRI of uterine malignant mixed Müllerian tumors versus endometrial carcinomas with emphasis on dynamic enhancement characteristics , 2019, Abdominal Radiology.

[2]  X. Zhang,et al.  MR imaging features and staging of neuroendocrine carcinomas of the uterine cervix with pathological correlations , 2016, European Radiology.

[3]  B. Clarke,et al.  Neuroendocrine tumors of the gynecologic tract: select topics. , 2013, Seminars in diagnostic pathology.

[4]  E. Eisenhauer,et al.  Neuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage disease. , 2013, Gynecologic oncology.

[5]  E. Sala,et al.  The revised FIGO staging system for uterine malignancies: implications for MR imaging. , 2012, Radiographics : a review publication of the Radiological Society of North America, Inc.

[6]  E. Sala,et al.  Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology , 2011, European Radiology.

[7]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[8]  S. Pecorelli Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium , 2009 .

[9]  D. Chi,et al.  Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy. , 2009, Gynecologic oncology.

[10]  Jen-Ruei Chen,et al.  Neuroendocrine Carcinoma of the Uterine Cervix: A Clinicopathologic Retrospective Study of 31 Cases with Prognostic Implications , 2006, Journal of chemotherapy.

[11]  K. Kim,et al.  MRI of small cell carcinoma of the uterine cervix with pathologic correlation. , 2004, AJR. American journal of roentgenology.

[12]  R. Burger,et al.  Prognostic factors in neuroendocrine small cell cervical carcinoma , 2003, Cancer.

[13]  Roy Zhang,et al.  Multiple biopsies and detection of cervical cancer precursors at colposcopy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.